Quick Answer
UroGen Pharma Ltd. reported Cash and Equivalents of $110.75 million for fiscal year 2025.
UroGen Pharma Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $110.75M | -35.6% |
| 2024 | $171.99M | +81.0% |
| 2023 | $95.00M | +71.5% |
| 2022 | $55.41M | +24.9% |
| 2021 | $44.36M | -16.1% |
| 2020 | $52.86M | +6.4% |
| 2019 | $49.69M | -51.0% |
| 2018 | $101.32M | +173.8% |
| 2017 | $37.00M | +73.2% |
| 2016 | $21.36M | +18.8% |
| 2015 | $17.98M | +364.5% |
| 2014 | $3.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.04M | -27.9% | -3.1% |
| June 30, 2025 | $92.90M | -57.8% | -10.7% |
| March 31, 2025 | $104.03M | -20.9% | -39.5% |
| December 31, 2024 | $171.99M | +81.0% | +37.7% |
| September 30, 2024 | $124.92M | +4.7% | -43.2% |
| June 30, 2024 | $219.97M | +992.9% | +67.4% |
| March 31, 2024 | $131.44M | +259.7% | +38.4% |
| December 31, 2023 | $95.00M | +71.5% | -20.4% |
- UroGen Pharma Ltd. showed a decrease of -35.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, UroGen Pharma Ltd.’s cash and equivalents has grown by 2761.6% (from $3.87 million to $110.75 million).
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: